Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured from Deceased Donors with High Kidney Donor Profile Index (KDPI)


About this study

The purpose of this study is to assess the feasibility and safety of delivering adipose mesenchymal stem cells (AMSCs) to kidney allografts.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male or female kidney transplant candidates age 18 and above.
  • Patient is receiving kidney allograft from deceased donor with KDPI > 60%.
  • Ability of subject to give appropriate consent.
  • Females of childbearing potential with agreement to use birth control for six months post-transplant.
  • Approved by the Mayo Clinic Transplant Selection Committee.
  • Signed Authorization for Donation of Anatomical Gifts on file.

Exclusion Criteria:

  • Positive pregnancy test at the time of the kidney offer is called for the potential recipient. 
  • Kidney transplant potential recipients with active malignancy (except non-melanoma skin malignancies).  
  • Patients with previous history of solid organ transplant (Heart, Lung, Intestine, Kidney and/or Pancreas).
  • Patients with previous history of bone marrow transplant.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Tambi Jarmi, M.D.

Open for enrollment

Contact information:

Elizabeth Starck

(904) 953-7971


More information


Publications are currently not available